Arthur F Ryan sold $90k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $899.61, traded May 1, 2024, filed May 3, 2024.
Score components
- +15RoleDirector
- +9Trade size$90k at market
- 0Share of holdings soldSold 0.5% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.4%, 3m +13.1%, 6m -11.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001883850-24-000017, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $889.50 | $2,669 | 18,179 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $890.75 | $1,782 | 18,177 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -7 | $891.52 | $6,241 | 18,170 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -9 | $892.50 | $8,033 | 18,161 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -5 | $893.16 | $4,466 | 18,156 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $895.38 | $1,791 | 18,154 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3 | $896.59 | $2,690 | 18,151 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -9 | $897.68 | $8,079 | 18,142 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -17 | $898.51 | $15k | 18,125 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -7 | $899.37 | $6,296 | 18,118 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -5 | $900.45 | $4,502 | 18,113 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $901.41 | $3,606 | 18,109 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $902.66 | $903 | 18,108 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $903.35 | $903 | 18,107 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $904.80 | $905 | 18,106 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $905.50 | $1,811 | 18,104 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $906.26 | $3,625 | 18,100 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -2 | $907.54 | $1,815 | 18,098 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $909.49 | $3,638 | 18,094 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -6 | $910.47 | $5,463 | 18,088 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -4 | $911.39 | $3,646 | 18,084 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $912.29 | $912 | 18,083 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1 | $913.21 | $913 | 18,082 | May 3, 2024 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.